Brief: Nextcell Invests In Car-T Technology

NextCell Pharma AB

08/02/2022 13:33

Feb 8 (Reuters) - NextCell Pharma AB  NXTCL.ST :
    * NEXTCELL INVESTS IN CAR-T TECHNOLOGY
    * FAMICORDTX, A JOINT VENTURE CELL-GENE BIOPHARMA COMPANY
ISSUES
NEW SHARE
    * PROCEEDS FROM ISSUE WILL BE USED TO FUND PHASE 1 CLINICAL
TRIALS
OF CAR T (CHIMERIC ANTIGEN RECEPTOR T CELL) THERAPY
    * WILL PARTICIPATE AT 50% OF THEIR PRO RATA RIGHTS
    * AN INVESTMENT OF APPROXIMATELY KEUR 160
    * OWNERSHIP IN FAMICORDTX WILL CHANGE FROM 9,43% TO 8,45% OF
THEN
SHARES
    * FAMICORDTX S.A., RAISED PLN 16 MILLION (APPROXIMATLY MEUR
3,5)
FROM A PRE-IPO ISSUE OF SHARES

Source text for Eikon:  ID:nWkr6Jjtzb 
Further company coverage:  NXTCL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))